Skip to Content

Axanum Approval Status

Axanum (aspirin/esomeprazole) is an investigational low dose aspirin esomeprazole combination for the risk reduction of low dose aspirin-associated gastric and/or duodenal ulcers.

In June 2010, AstraZeneca announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Axanum (aspirin/esomeprazole magnesium) tablets had not been approved.

Development Status and FDA Approval Process for Axanum

Jun  1, 2010AstraZeneca Receives FDA Complete Response Letter for Axanum New Drug Application
May  4, 2009AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.